Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1878-1884

  Baechler, Sébastien ^a,b   Hobbs, Robert F ^b   Jacene, Heather A ^b   Bochud, François O ^a   Wahl, Richard L ^b   Sgouros, George ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

131I tositumomab; 90Y ibritumomab tiuxetan; Hematologic toxicity; Radioimmunotherapy

Indexed keywords

FLUDARABINE; IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE LINEAR REGRESSION ANALYSIS; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; BONE MARROW; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKOCYTE COUNT; LINEAR MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; THROMBOCYTOPENIA; YTTRIUM RADIOISOTOPES;

EID: 78651337133     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079947     Document Type: Article

References (22)

1. 131 tositumomab. Oncogene. 2007;26:3614-3628.
2. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712-719.
3. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
4. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
5. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
6. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
7. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)
8. 131I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med. 1999;40:1609-1616.
9. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
10. 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-1776.
11. Zevalin prescribing information [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2009. Available at: http://www.zevalin.com/v3/pdf/ Zevalin-Package-Insert.pdf. Accessed October 25, 2010.
12. 90Y- ibritumomab tiuxetan. J Nucl Med. 2009;50:644-652.
13. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000;27:2150-2164.
14. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8, suppl):14S-20S.
15. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003;30:31-38.
16. Bexxar prescribing information [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005. Available at: http://us.gsk.com/products/assets/us- bexxar.pdf. Accessed October 25, 2010.
17. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435-443.
18. 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:458-469.
19. Rosner GL, Muller P. Pharmacodynamic analysis of hematologic profiles. J Pharmacokinet Biopharm. 1994;22:499-524.
20. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
21. Gregory SA, Leonard J, Knox SJ, Zelenetz A, Armitage JO, Kaminski M. The iodine I-131 tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma [abstract]. J Clin Oncol. 2004;22(July 15 suppl):6732.
22. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94(4, suppl):1332-1348.